Addition of Pembrolizumab Shows Benefit in Oligometastatic NSCLC - Cancer Therapy Advisor

Addition of Pembrolizumab Shows Benefit in Oligometastatic NSCLC  Cancer Therapy Advisor

The addition of pembrolizumab after locally ablative therapy appeared to improve clinical outcomes for patients with oligometastatic non-small cell lung cancer.



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...

Stage 4 Lung Cancer Life Expectancy